WCLC 2025 - Posters & ePosters-P3.18.63 Phase 1 Study of FHND5071, a Novel Selective RET Inhibitor, in RET Fusion-Positive Advanced NSCLC

P3.18.63 Phase 1 Study of FHND5071, a Novel Selective RET Inhibitor, in RET Fusion-Positive Advanced NSCLC

Asset Subtitle

Dechuang Yuan

Meta Tag

Speaker Dechuang Yuan

Topic Clinical Trials in Progress